Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Clinical Microbiology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mycology

Syscan3, a Kit for Detection of Anti-Candida Antibodies for Diagnosis of Invasive Candidiasis

Annie Philip, Zekaver Odabasi, Gloria Matiuzzi, Victor L. Paetznick, Sze-Wee Tan, John Warmington, John H. Rex, Luis Ostrosky-Zeichner
Annie Philip
1Laboratory of Mycology Research, University of Texas—Houston Medical School, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zekaver Odabasi
1Laboratory of Mycology Research, University of Texas—Houston Medical School, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gloria Matiuzzi
2University of Texas M. D. Anderson Cancer Center, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victor L. Paetznick
1Laboratory of Mycology Research, University of Texas—Houston Medical School, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sze-Wee Tan
3Rockeby Biomed, Ltd., Western Australia, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Warmington
3Rockeby Biomed, Ltd., Western Australia, Australia
4School of Biomedical Sciences, Curtin University of Technology, Bentley, Western Australia, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John H. Rex
1Laboratory of Mycology Research, University of Texas—Houston Medical School, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luis Ostrosky-Zeichner
1Laboratory of Mycology Research, University of Texas—Houston Medical School, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Luis.Ostrosky-Zeichner@uth.tmc.edu
DOI: 10.1128/JCM.43.9.4834-4835.2005
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Sera from 76 immunocompetent and 293 immunocompromised subjects were assayed for anti-Candida antibodies. The sensitivity, specificity, positive predictive value, and negative predictive value for invasive candidiasis were 74%, 75%, 62%, and 84% in the immunocompetent group and 15%, 60%, 1.7%, and 93% in the immunocompromised group, respectively. Syscan3 has high negative predictive value.

Despite a recent trend of emerging mold infections among immunocompromised patients, candidemia is still the fourth most common nosocomial bloodstream infection in the United States (9). Attributable mortality rates are usually between 38 and 49% (7). It is well known that Candida is cultured from blood in only 50 to 70% of patients with disseminated candidiasis (4).

Diagnostic markers for invasive candidiasis have long been sought. Detection systems for metabolites (e.g., fungal d-arabinitol, (5, 10), fungal DNA by PCR (1, 8, 11), and fungal cell wall components (e.g., β-d-glucan) (13, 14) have all been investigated, but none has yet achieved broad validation. Assays for fungal antigens (or antibodies to same) have also been studied, but generally with little success (16).

The anti-Candida antibody approaches studied to date have included the Virotech and Biomerica kits (both use polyclonal antibodies) and the monoclonal antibody-based Platelia Candida kit. These kits have shown sensitivities ranging from 50 to 90% and specificities of ∼15 to 65% (15). As its use of a mixture of target antigens offered the potential for increased diagnostic power, we evaluated a new anti-Candida antibody detection enzyme-linked immunosorbent assay-based kit (Syscan3; Rockeby Biomed Ltd.) as a potential adjunct for the diagnosis of invasive candidiasis.

Patient samples.

Two frozen (−80°C) deidentified and anonymized serum collections were used. Collection A consisted of 76 subjects: 27 hospitalized patients with proven invasive candidiasis (26 with candidemia and 1 with candidal peritonitis), 6 hospitalized patients with noncandidal fungal infections (4 with cryptococcosis and 2 with invasive mold infections), and 43 healthy control subjects. The Candida species distribution was as follows: C. albicans, 16/27; C. glabrata, 4/27; C. tropicalis, 3/27; coinfection with C. albicans and C. glabrata, 2/27; and C. krusei and C. parapsilosis, 1 each. Sera from patients with invasive candidiasis were drawn within 96 h of the positive culture. Collection B consisted of sera collected twice weekly from 293 patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy and receiving antifungal prophylaxis with either itraconazole or caspofungin. Thirteen of these patients were found to have proven or probable invasive candidiasis. The species distribution was as follows: C. glabrata, 7/13; C. albicans, 2/13; C. krusei, 2/13; and C. parapsilosis and C. tropicalis, 1 each. A single sample was selected for testing from each patient. For patients with invasive candidiasis, a sample was selected within 96 h of the diagnosis or the positive culture. For uninfected patients; the first available sample was utilized. Invasive candidiasis was defined according to the EORTC/MSG criteria (3). This study was approved by the UTHSCH Institutional Review Board.

Testing method.

Syscan3 testing kits were provided by Rockeby Biomed Ltd. (Western Australia, Australia). Samples from each collection were mixed with a phosphate-buffered saline diluent (10 μl of serum mixed into 990 μl of serum diluent). One hundred microliters of the respective dilutions was deposited into the wells of a 96-well microdilution tray in which the wells had been coated with a proprietary mixture of purified intracytoplasmic Candida antigens, with enolase as the predominant antigen. Samples were incubated for 45 min at room temperature, washed, and incubated with horseradish peroxidase-conjugated antihuman antibodies for 45 min. After washing the wells with buffer, a peroxidase solution and acid stop solution were added. Sample absorbance was read using a dual-wavelength spectrophotometer at 450 nm with a reference of 650 nm. The kit also included positive, negative, and cutoff controls. Controls and sera were tested in duplicate. The reading for each test sample was determined in arbitrary units as (sample absorbance × 10)/(mean absorbance of cutoff control sample). The negative and positive controls had to fall within predetermined quality control ranges to accept the results as valid. A cutoff of ≥15 U was selected based on a preliminary study by the kit developers and by determining receiver operating characteristic curves with collection A (data not shown). Means of units between groups were compared by t test (SPSS 12.0.1; SPPS, Inc.), and diagnostic test performance was evaluated using standard formulas.

Results.

For collection A, the mean numbers of units ± standard deviation in patients versus controls were 20.78 ± 6.81 U and 11.24 ± 5.94 U (P < 0.0001). For collection B, the mean numbers of units ± standard deviation in patients versus controls were 10.98 ± 6.58 U and 13.85 ± 6.98 U (P = 0.15). Using the cutoff of ≥15 U, for collection A, 20 of the 27 patients with invasive candidiasis were detected by Syscan3, while only 2 of 13 patients in collection B were identified. All of the patients with non-Candida fungal infections had negative results. As shown in Table 1, the sensitivity, specificity, positive predictive value, and negative predictive value for collection A were 74%, 75%, 62%, and 84%, respectively, while for collection B they were 15%, 60%, 1.7%, and 93%. Decreasing or increasing the cutoff for collection B did not improve the performance of the test.

View this table:
  • View inline
  • View popup
TABLE 1.

Diagnostic performance of SysCan3 with immunocompetent and immunocompromised hosts

Our evaluation of Syscan3 in both collections A and B yielded relatively high negative predictive values when compared to previously available commercial kits (15), thus offering a good possibility of “ruling out” the disease. The significance of the negative and positive predictive values should be approached with caution in collection A since these values rely on the prevalence of disease in the study population, which in the case of this collection, was artificially constructed (12). In the immunocompromised hematological patients evaluated in collection B, sensitivity and positive predictive values were low. Of note, the mean test results for the cases in collection B were similar to the values of controls in both collections. This might be due to reduced antibody production in the immunocompromised population (6) or the use of antifungal prophylaxis, thus preemptively treating infections in this subject group. Although the negative predictive value appears to be fairly good for collection B, the negative likelihood ratio is 0.38; thus, a negative test may result in only a small decrease in the probability that a patient in this population has an invasive Candida infection. Nevertheless, a statistical artifact related to the low prevalence of the studied disease cannot be excluded (12).

In summary, the Syscan3 kit offers reasonable negative predictive value. A prospective, multicenter evaluation of Syscan3 kit is needed to further evaluate its clinical usefulness in immunocompetent and other immunocompromised patients (e.g., human immunodeficiency virus-infected and organ transplant patients), as well as settings (such as intensive care units) with a high prevalence of invasive candidiasis. The effects of Candida colonization and superficial Candida infections remain to be studied. Also, repeat testing with multiple samples during the course of infection may help in more accurately diagnosing invasive candidiasis, as has been previously noted with other serological tests (2, 6, 17).

ACKNOWLEDGMENTS

This work was supported by a grant from Rockeby Biomed, Ltd., Western Australia, Australia.

FOOTNOTES

    • Received 9 February 2005.
    • Returned for modification 6 May 2005.
    • Accepted 28 June 2005.
  • Copyright © 2005 American Society for Microbiology

REFERENCES

  1. 1.↵
    Ahmad, S., A. S. Mustafa, Z. Khan, A. I. Al-Rifaiy, and Z. U. Khan. 2004. PCR-enzyme immunoassay of rDNA in the diagnosis of candidemia and comparison with amplicon detection by agarose gel electrophoresis. Int. J. Med. Microbiol.294:45-51.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Alexander, B. D. 2002. Diagnosis of fungal infection: new technologies for the mycology laboratory. Transplant. Infect. Dis.4(Suppl. 3):32-37.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Ascioglu, S., J. H. Rex, B. de Pauw, J. E. Bennett, J. Bille, F. Crokaert, D. W. Denning, J. P. Donnelly, J. E. Edwards, Z. Erjavec, D. Fiere, O. Lortholary, J. Maertens, J. F. Meis, T. F. Patterson, J. Ritter, D. Selleslag, P. M. Shah, D. A. Stevens, and T. J. Walsh. 2002. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis.34:7-14.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    Berenguer, J., M. Buck, F. Witebsky, F. Stock, P. A. Pizzo, and T. J. Walsh. 1993. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn. Microbiol. Infect. Dis.17:103-109.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    Christensson, B., G. Sigmundsdottir, and L. Larsson. 1999. d-Arabinitol—a marker for invasive candidiasis. Med. Mycol.37:391-396.
    OpenUrlCrossRefPubMed
  6. 6.↵
    Denning, D. W., E. G. Evans, C. C. Kibbler, M. D. Richardson, M. M. Roberts, T. R. Rogers, D. W. Warnock, R. E. Warren et al. 1997. Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. Eur. J. Clin. Microbiol. Infect. Dis.16:424-436.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    Gudlaugsson, O., S. Gillespie, K. Lee, J. Vande Berg, J. Hu, S. Messer, L. Herwaldt, M. Pfaller, and D. Diekema. 2003. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis.37:1172-1177.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    Iwen, P. C., A. G. Freifeld, T. A. Bruening, and S. H. Hinrichs. 2004. Use of a panfungal PCR assay for detection of fungal pathogens in a commercial blood culture system. J. Clin. Microbiol.42:2292-2293.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    Jarvis, W. R. 1995. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin. Infect. Dis.20:1526-1530.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    Kiehn, T. E., E. M. Bernard, J. W. Gold, and D. Armstrong. 1979. Candidiasis: detection by gas-liquid chromatography of d-arabinitol, a fungal metabolite, in human serum. Science206:577-580.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    Maaroufi, Y., C. Heymans, J.-M. De Bruyne, V. Duchateau, H. Rodriguez-Villalobos, M. Aoun, and F. Crokaert. 2003. Rapid detection of Candida albicans in clinical blood samples by using a TaqMan-based PCR assay. J. Clin. Microbiol.41:3293-3298.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    Moyer, V. A., and K. A. Kennedy. 2003. Understanding and using diagnostic tests. Clin. Perinatol.30:189-204.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    Obayashi, T., M. Yoshida, T. Mori, H. Goto, A. Yasuoka, H. Iwasaki, H. Teshima, S. Kohno, A. Horiuchi, A. Ito et al. 1995. Plasma (1→3)-beta-d-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet345:17-20.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    Odabasi, Z., G. Mattiuzzi, E. Estey, H. Kantarjian, F. Saeki, R. J. Ridge, P. A. Ketchum, M. A. Finkelman, J. H. Rex, and L. Ostrosky-Zeichner. 2004. Beta-d-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin. Infect. Dis.39:199-205.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    Persat, F., R. Topenot, M. A. Piens, A. Thiebaut, E. Dannaoui, and S. Picot. 2002. Evaluation of different commercial ELISA methods for the serodiagnosis of systemic candidosis. Mycoses45:455-460.
    OpenUrlPubMedWeb of Science
  16. 16.↵
    Phillips, P., A. Dowd, P. Jewesson, G. Radigan, M. G. Tweeddale, A. Clarke, I. Geere, and M. Kelly. 1990. Nonvalue of antigen detection immunoassays for diagnosis of candidemia. J. Clin. Microbiol.28:2320-2326.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    Walsh, T. J., J. W. Hathorn, J. D. Sobel, W. G. Merz, V. Sanchez, S. M. Maret, H. R. Buckley, M. A. Pfaller, R. Schaufele, C. Sliva et al. 1991. Detection of circulating candida enolase by immunoassay in patients with cancer and invasive candidiasis. N. Engl. J. Med.324:1026-1031.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
Syscan3, a Kit for Detection of Anti-Candida Antibodies for Diagnosis of Invasive Candidiasis
Annie Philip, Zekaver Odabasi, Gloria Matiuzzi, Victor L. Paetznick, Sze-Wee Tan, John Warmington, John H. Rex, Luis Ostrosky-Zeichner
Journal of Clinical Microbiology Sep 2005, 43 (9) 4834-4835; DOI: 10.1128/JCM.43.9.4834-4835.2005

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Clinical Microbiology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Syscan3, a Kit for Detection of Anti-Candida Antibodies for Diagnosis of Invasive Candidiasis
(Your Name) has forwarded a page to you from Journal of Clinical Microbiology
(Your Name) thought you would be interested in this article in Journal of Clinical Microbiology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Syscan3, a Kit for Detection of Anti-Candida Antibodies for Diagnosis of Invasive Candidiasis
Annie Philip, Zekaver Odabasi, Gloria Matiuzzi, Victor L. Paetznick, Sze-Wee Tan, John Warmington, John H. Rex, Luis Ostrosky-Zeichner
Journal of Clinical Microbiology Sep 2005, 43 (9) 4834-4835; DOI: 10.1128/JCM.43.9.4834-4835.2005
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • Patient samples.
    • Testing method.
    • Results.
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Antibodies, Fungal
Candida
candidiasis
fungemia
Reagent Kits, Diagnostic

Related Articles

Cited By...

About

  • About JCM
  • Editor in Chief
  • Board of Editors
  • Editor Conflicts of Interest
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Resources for Clinical Microbiologists
  • Ethics
  • Contact Us

Follow #JClinMicro

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

 

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0095-1137; Online ISSN: 1098-660X